Psoriasis Treatment Guide

Psoriasis affects roughly 3.2% of the U.S. population — somewhere between 7.5 and 8 million Americans — and has long been mischaracterized as a purely cosmetic condition.^[1] In reality, it is a chronic, systemic immune-mediated inflammatory disease. The visible plaques are just the most obvious signal of immune dysregulation that also drives cardiovascular disease, metabolic syndrome, joint destruction, and depression.

What I tell patients who come in frustrated after years of suboptimal treatment is this: the field has changed dramatically. A decade ago, moderate-to-severe psoriasis often meant cycling through topicals until something worked, then tolerating side effects from older systemic drugs. Today, biologics targeting specific cytokine pathways achieve complete or near-complete skin clearance in the majority of patients who qualify. The challenge is identifying those patients, matching them to the right therapy, and making sure nothing is missed in the bigger clinical picture.

This guide walks through everything that matters clinically: the types of psoriasis, how they're graded, what the AAD-NPF guidelines actually say, how to think about treatment selection, and why this condition demands attention to more than just what's on the surface.

Types of Psoriasis

Psoriasis is not a single disease. The term encompasses several distinct clinical subtypes, each with different presentations, triggers, and treatment implications. Knowing the subtype matters because treatment response and risk of complications vary meaningfully.

Plaque Psoriasis (Psoriasis Vulgaris)

This is the form most people picture when they hear "psoriasis." It accounts for 80–90% of all cases.^[1] Plaque psoriasis presents as well-demarcated, raised, erythematous plaques covered by thick silvery-white scale. Classic locations include the elbows, knees, scalp, lower back, and sacral area. The Koebner phenomenon — where new plaques appear at sites of skin trauma — is characteristic. Pruritus is common and often undertreated.

Guttate Psoriasis

Guttate psoriasis appears as small (less than 1 cm), drop-shaped, salmon-colored papules scattered across the trunk and extremities. It most commonly affects children and young adults and is strongly associated with preceding streptococcal pharyngitis. Many patients experience a single episode that resolves; some go on to develop chronic plaque psoriasis. Phototherapy is highly effective for guttate flares.

Inverse (Intertriginous) Psoriasis

Rather than the typical thick scale of plaque disease, inverse psoriasis presents as smooth, shiny, well-defined red plaques in skin folds — the axillae, groin, under the breasts, and perianal area. The moist microenvironment eliminates the scale but also makes the diagnosis easy to confuse with fungal infections, contact dermatitis, or intertrigo. High-potency steroids are not appropriate here due to the risk of atrophy; calcineurin inhibitors are the preferred topical option.

Pustular Psoriasis

Pustular psoriasis is characterized by sterile (non-infectious) pustules on erythematous skin. It has two major forms: localized palmoplantar pustulosis, which is confined to the palms and soles and is relatively manageable, and generalized pustular psoriasis (GPP), which is a serious and potentially life-threatening variant with widespread pustules, fever, and systemic illness. GPP requires urgent medical attention. Cyclosporine is the traditional first-line agent for GPP flares; spesolimab, an IL-36 receptor antagonist, received FDA approval in 2022 specifically for GPP.

Erythrodermic Psoriasis

Erythrodermic psoriasis covers more than 90% of body surface area with a diffuse, fiery erythema. It is rare but medically serious — the disrupted skin barrier leads to temperature dysregulation, fluid and electrolyte imbalance, and secondary infection risk. This is a dermatologic emergency. Triggers include abrupt withdrawal of systemic corticosteroids, which is one of several reasons steroids are generally avoided in psoriasis management.

AAD-NPF Joint Guidelines: What They Say

The American Academy of Dermatology and the National Psoriasis Foundation published five joint guideline sections between 2019 and 2021, covering biologics, phototherapy, systemic non-biologic therapies, topical therapy, and comorbidities.^[2] Together they represent the most thorough current evidence synthesis for psoriasis management in adults.

One of the more practically useful insights from the guidelines: PASI is recommended primarily for clinical trials, not routine practice. For day-to-day clinical decision-making, BSA combined with a quality-of-life instrument like the DLQI (Dermatology Life Quality Index) gives a more actionable picture of disease burden.

PASI Scoring: The Basics

Even though PASI is most relevant to clinical trials, you will encounter it in any discussion of biologic therapy. Understanding the scoring helps patients and clinicians communicate about treatment goals.

PASI divides the body into four regions — head (10% of BSA), upper extremities (20%), trunk (30%), and lower extremities (40%). Each region is assessed for three severity parameters: erythema (redness), induration (thickness/elevation), and desquamation (scaling), each scored 0–4. These are then multiplied by the extent of involvement in that region (scored 0–6) and by the regional body weight factor. The four regional scores are summed for a total between 0 and 72.^[7]

The clinical benchmarks used in biologic trials:

Topical Therapy: The Corticosteroid Potency Ladder and Steroid-Sparing Options

For mild-to-moderate psoriasis or as an adjunct to systemic therapy, topicals remain the first step. The AAD-NPF topical guideline provides clear direction on agent selection, potency, and site-appropriate use.^[3]

Corticosteroids: The Potency Ladder

Topical corticosteroids are the most widely used treatment in psoriasis. They work by suppressing local inflammation, reducing keratinocyte proliferation, and causing vasoconstriction. Potency is the key variable in selection — and using the wrong potency for a given body site is a common error that leads to either treatment failure or skin damage.

For long-term management, the guidelines recommend alternating steroid use with steroid-sparing agents to minimize adverse effects — including skin atrophy, striae, and adrenal suppression from extensive application of high-potency agents.

Vitamin D Analogues: Calcipotriene

Calcipotriene (calcipotriol) is a synthetic vitamin D analogue that slows keratinocyte proliferation and normalizes cell differentiation without the atrophy risk of steroids. It is frequently combined with betamethasone dipropionate — the combination product (Taclonex ointment or Enstilar foam) has become a mainstay of topical psoriasis therapy, offering superior efficacy to either agent alone and reducing the frequency of steroid application needed.^[3] Calcipotriene should not be applied to the face or intertriginous areas and should be used with caution in patients with calcium metabolism disorders.

Tazarotene

Tazarotene is a topical retinoid that normalizes keratinocyte differentiation and has anti-inflammatory properties. Used alone, it can cause irritation and is more effective when combined with a topical corticosteroid, which also reduces local irritation. The guidelines support tazarotene for skin and nail psoriasis. It is teratogenic and must not be used in pregnancy or in women planning to conceive.

Calcineurin Inhibitors for Special Sites

Tacrolimus and pimecrolimus are not FDA-approved for psoriasis but have well-established off-label use for face and genital psoriasis, where steroid-related atrophy is a significant concern. The AAD-NPF guidelines explicitly recommend calcineurin inhibitors for these areas, either alone or in combination with low-potency steroids.^[3]

Phototherapy: Narrowband UVB and Excimer Laser

Phototherapy sits between topical and systemic therapy in the treatment algorithm. It is particularly appropriate for patients with moderate-to-severe psoriasis who want to avoid systemic medications, have multiple comorbidities that complicate systemic use, or are pregnant.

Narrowband UVB (NB-UVB)

Narrowband UVB delivers light at 311–313 nm — a wavelength that targets the immunologic pathways driving psoriatic plaques while minimizing the carcinogenic and erythematous wavelengths. NB-UVB is now the standard phototherapy modality, having largely replaced broadband UVB (BB-UVB) due to superior efficacy and a better safety profile.

Treatments are given 2–3 times weekly, with most patients seeing meaningful improvement within 20–30 sessions. Approximately 62–70% of patients achieve PASI 75 with a full NB-UVB course.^[8] A landmark 2024 randomized clinical trial — the LITE study — demonstrated that home-based NB-UVB phototherapy is as effective as office-based treatment across all skin types, with less burden to patients and comparable safety.^[9] This finding has significant implications for access, particularly for patients in rural or underserved areas.

NB-UVB can be combined with topical therapy (especially calcipotriene) for additive effect, or with systemic agents for difficult-to-clear disease. Long-term cumulative UVB exposure increases the risk of non-melanoma skin cancer, though this risk is substantially lower than with PUVA (psoralen plus UVA).

Excimer Laser

The 308-nm excimer laser delivers targeted UVB to individual plaques without exposing uninvolved skin. It is particularly useful for localized, recalcitrant plaques — elbows, knees, or scalp patches that haven't responded to topicals. Because treatment is targeted, it achieves clearance faster than broad-panel phototherapy for small areas, typically within 10–20 sessions. The AAD-NPF phototherapy guideline supports excimer laser for chronic localized plaque psoriasis.^[4]

Systemic Therapy: Methotrexate, Cyclosporine, and Apremilast

When topicals and phototherapy are insufficient for moderate-to-severe disease, or when the patient's circumstances make phototherapy impractical, systemic non-biologic agents become the next consideration. The AAD-NPF systemic guidelines cover methotrexate, cyclosporine, and apremilast as primary agents.^[2]

Methotrexate

Methotrexate (MTX) has been used in psoriasis for over 60 years and remains the most prescribed systemic agent globally. It works by inhibiting folate metabolism, which dampens keratinocyte proliferation and T-cell activation. Typical dosing is 10–25 mg weekly (oral or subcutaneous), with folic acid supplementation to reduce mucosal and hematologic side effects.

The major concern with long-term MTX use is hepatotoxicity and hepatic fibrosis. The 2021 AAD-NPF systemic guidelines updated hepatotoxicity monitoring to recommend non-invasive tests — specifically hepatic elastography (FibroScan) and serum fibrosis markers — rather than routine liver biopsy, which had been standard for decades.^[2] MTX is also effective for psoriatic arthritis, making it a useful choice when both skin and joint disease need treatment.

Cyclosporine

Cyclosporine acts rapidly — often showing results within 2–4 weeks — making it useful for acute flares, erythrodermic episodes, and pustular psoriasis. It is a calcineurin inhibitor that suppresses T-cell activation broadly. The significant drawbacks are nephrotoxicity and hypertension with prolonged use, which limit cyclosporine to short courses (typically no longer than 1–2 years) or bridge therapy. Blood pressure and renal function require regular monitoring throughout treatment.

Apremilast

Apremilast (Otezla) is an oral phosphodiesterase-4 (PDE-4) inhibitor approved for moderate-to-severe plaque psoriasis and psoriatic arthritis. It has a favorable safety profile compared to older systemic agents — no required lab monitoring after initiation, no immunosuppression concerns, and no teratogenicity issues of the same magnitude. Efficacy is more modest than biologics (PASI 75 rates of approximately 30–40%), but apremilast fills an important role for patients who cannot or prefer not to use injectable therapies, and for those with comorbidities that preclude immunosuppressive agents. It also shows benefit for oral and genital psoriasis. The most common side effects are gastrointestinal — nausea and diarrhea — typically occurring in the first few weeks.

Biologics: TNF-Alpha, IL-17, and IL-23 Inhibitors

Biologics have fundamentally changed the treatment potential for moderate-to-severe psoriasis. These are injectable or infused agents that target specific proteins in the inflammatory cascade driving psoriasis. They are approved for patients who have not responded adequately to topical therapy, phototherapy, or conventional systemic agents — or for whom those options are contraindicated.^[2]

TNF-Alpha Inhibitors

The TNF-alpha inhibitors — etanercept, adalimumab, infliximab, and certolizumab — were the first biologic class approved for psoriasis and have the longest safety track record. They work by blocking tumor necrosis factor-alpha, a pro-inflammatory cytokine central to the psoriatic cascade. Adalimumab and etanercept remain commonly used; infliximab is reserved for severe or recalcitrant disease due to its infusion route. TNF inhibitors achieve PASI 75 in roughly 50–75% of patients — effective, but generally lower rates than the newer cytokine-specific biologics. They are well-studied in psoriatic arthritis as well. Key precautions include tuberculosis reactivation risk (baseline and annual TB testing required), and caution in patients with active or recent serious infections, demyelinating disease, or heart failure.

IL-17 Inhibitors

The IL-17 pathway is central to psoriatic inflammation. IL-17A, produced primarily by Th17 cells, acts on keratinocytes to drive the rapid skin cell turnover and inflammatory milieu that characterizes plaque psoriasis. Blocking this pathway produces rapid and dramatic clearance.

Secukinumab (Cosentyx), approved in January 2015, was the first IL-17A inhibitor for psoriasis. In key phase III trials, secukinumab achieved PASI 90 in approximately 59% of patients and PASI 100 in about 28% — a level of clearance that was unprecedented compared to prior biologics.^[5] It is dosed monthly after a loading phase and is also approved for psoriatic arthritis and ankylosing spondylitis. Ixekizumab (Taltz) is a related IL-17A inhibitor with similar efficacy profiles. Brodalumab (Siliq) blocks the IL-17 receptor rather than the cytokine itself, producing equally strong clearance rates. The IL-17 class achieves particularly strong results at special sites — scalp and nail psoriasis respond better to IL-17 inhibitors than to other biologic classes.^[6]

IL-23 Inhibitors

IL-23 sits upstream of IL-17 — it drives the differentiation and proliferation of Th17 cells. Blocking IL-23 more selectively targets the psoriatic process while leaving broader immune surveillance intact. The p19 subunit-specific IL-23 inhibitors — guselkumab (Tremfya), risankizumab (Skyrizi), and tildrakizumab (Ilumya) — represent the current high point of biologic efficacy and durability.

Risankizumab, in head-to-head trials, achieved PASI 90 in 72% and PASI 100 in approximately 56% of patients at 52 weeks, with sustained responses seen through 5 years of follow-up. Drug survival studies show risankizumab and guselkumab have among the highest long-term continuation rates of any biologic — meaning patients who achieve clearance tend to maintain it and stay on the drug.^[10] For patients who prioritize complete clearance and durability, IL-23 inhibitors are typically the first-choice biologic in current clinical practice, consistent with AAD-NPF guidance that supports biologics as a first-line systemic option for moderate-to-severe disease.^[2]

Psoriatic Arthritis Screening

Psoriatic arthritis (PsA) develops in approximately 20–30% of psoriasis patients, yet it frequently goes undiagnosed for years. Joint damage from PsA begins early and can become irreversible. By the time a patient notices significant joint symptoms, structural damage may already be present on imaging. This is why systematic screening at every psoriasis visit matters clinically, not just as a checkbox.

The AAD-NPF comorbidity guidelines explicitly call on dermatologists to screen all psoriasis patients for PsA and to refer to rheumatology when clinical suspicion is high.^[1]

What to Ask

In my clinical practice, joint assessment starts with five direct questions:

• Do you have pain, stiffness, or swelling in any joints?
• Is the stiffness worse in the morning, and does it last more than 30 minutes?
• Do you have pain at the heel, the bottom of the foot, or where tendons attach to bone?
• Has anyone ever told you that your fingers or toes look swollen like "sausages" (dactylitis)?
• Do you have nail pitting or separation of the nail from the nail bed?

Validated Screening Tools

Two validated questionnaires are widely used in non-rheumatology settings:

The PEST (Psoriasis Epidemiology Screening Tool) is a 5-item questionnaire with a sensitivity of 0.92 and specificity of 0.78 for identifying PsA in psoriasis patients.^[4] A score of 3 or higher prompts rheumatology referral. It is brief enough for routine clinic use and includes a visual body diagram for patients to indicate painful joints.

The ToPAS (Toronto Psoriatic Arthritis Screening questionnaire) covers skin, joint, and nail domains, demonstrating overall sensitivity of 86.8% and specificity of 93.1% at validated cut points.^[11] Both tools outperform clinical intuition alone and can be administered by nursing staff before the physician encounter.

When PsA is suspected, the workup typically includes inflammatory markers (ESR, CRP), rheumatoid factor (to distinguish from rheumatoid arthritis, though PsA is usually seronegative), and plain radiographs of affected joints. Early rheumatology involvement is associated with better long-term joint outcomes.

Special Site Management: Scalp, Nail, and Genital Psoriasis

These three locations require distinct approaches. Standard topical formulations designed for body plaques are often poorly tolerated or impractical at these sites, and the disease can persist despite adequate clearance elsewhere.

Scalp Psoriasis

Scalp involvement occurs in 45–56% of psoriasis patients and is often the most visible and socially distressing site.^[6] The hair impedes topical application, so vehicle matters as much as the active ingredient. For scalp psoriasis, the AAD-NPF guidelines recommend topical corticosteroids in the form of foams, gels, solutions, shampoos, or sprays rather than creams or ointments. Clobetasol foam (Olux) and betamethasone valerate lotion are commonly used first-line agents. Vitamin D analogues (calcipotriene solution) can be combined with scalp steroids. Keratolytic shampoos containing salicylic acid or coal tar help remove scale and improve penetration of active agents.

For patients with scalp disease that fails topical therapy, or those with concurrent moderate-to-severe body disease, systemic or biologic therapy is appropriate. IL-17 inhibitors — particularly ixekizumab — show 10–20% higher scalp clearance rates compared to other biologic classes in head-to-head analyses.^[6]

Nail Psoriasis

Nail involvement affects 10–55% of psoriasis patients and is present in up to 80% of those with PsA.^[6] Nail disease manifests as pitting (small depressions in the nail surface), onycholysis (separation of the nail plate from the nail bed), oil spots (yellow-brown discoloration under the nail), and subungual hyperkeratosis (thickened nail bed). These changes are not merely cosmetic — they can be painful and functionally limiting.

Nail psoriasis responds slowly to topicals due to the physical barrier of the nail plate. First-line topical options include calcipotriol with high-potency corticosteroid, with tazarotene and tacrolimus as second-line agents. Intralesional triamcinolone injections into the nail fold are effective for matrix disease but require patient tolerance of a procedure that can be uncomfortable. For moderate-to-severe nail disease, or when nail involvement accompanies PsA, systemic therapy — particularly biologics — is warranted. Apremilast shows measurable improvement in NAPSI (Nail Psoriasis Severity Index) scores. Brodalumab and ixekizumab have demonstrated strong nail-specific efficacy in phase III data.^[6]

Genital Psoriasis

Genital psoriasis affects approximately 33–40% of psoriasis patients at some point in their lives, and in 2–5% of cases it is the only site involved.^[6] Because this location is rarely volunteered by patients unless specifically asked, it is frequently underdiagnosed and undertreated. The condition causes significant quality-of-life impairment, including sexual dysfunction and psychological distress.

The thin skin and moist environment of the genital area contraindicate high-potency steroids, which carry substantial atrophy risk. Low-potency corticosteroids for short courses, combined with calcineurin inhibitors (tacrolimus or pimecrolimus) as the primary steroid-sparing agents, are the evidence-supported approach for localized disease. A randomized controlled trial showed crisaborole 2% ointment to be effective for intertriginous and genital psoriasis as a non-steroidal alternative. For systemic therapy, ixekizumab has demonstrated efficacy specifically for genital psoriasis in a phase III trial.^[6] Asking about genital involvement routinely — not waiting for patients to raise it — is part of complete psoriasis care.

Comorbidities: Cardiovascular Risk, Metabolic Syndrome, and Depression

The AAD-NPF comorbidity guideline frames psoriasis explicitly as a "chronic, inflammatory, multisystem disease" — not a skin condition that happens to have some associated health problems.^[1] This distinction matters clinically because the chronic systemic inflammation of psoriasis independently drives disease in other organ systems.

Cardiovascular Risk

Patients with moderate-to-severe psoriasis have significantly elevated cardiovascular risk compared to the general population. Chronic elevation of pro-inflammatory cytokines — TNF-alpha, IL-17, IL-6 — drives atherosclerosis, endothelial dysfunction, and arterial stiffness independent of traditional cardiovascular risk factors.^[12] Studies consistently show that standard cardiovascular risk calculators (Framingham Risk Score, QRISK3) underestimate actual risk in psoriasis patients, because they don't account for the inflammatory burden. This means the threshold for aggressive lipid and blood pressure management should be lower in psoriasis than in the general population with similar traditional risk profiles.

In practice, dermatologists should document cardiovascular risk factor screening at psoriasis visits and communicate findings to the patient's primary care provider. The guidelines also note that effective treatment of psoriasis with systemic biologics may itself reduce cardiovascular risk by lowering systemic inflammatory burden — an added benefit beyond skin clearance.

Metabolic Syndrome

Obesity, hypertension, dyslipidemia, and insulin resistance cluster together in psoriasis patients at rates well above the general population. Metabolic syndrome prevalence is elevated even in mild psoriasis, suggesting that shared inflammatory pathways — rather than disease severity alone — drive the association. Obesity is both a risk factor for psoriasis and a consequence of the reduced activity and psychological burden the disease imposes. Weight loss in obese patients with psoriasis has been associated with improved treatment response to biologics and other systemic agents, which is worth raising with patients regardless of their current BMI trajectory.

Depression and Mental Health

About 1 in 5 people with psoriasis also has depression, and the prevalence of anxiety is similar — approximately 20–21% for each condition in large epidemiologic studies.^[13] This is not simply stress about having a visible skin condition. Shared inflammatory mechanisms — particularly elevated IL-6, TNF-alpha, and IL-17 — link cutaneous and psychiatric disease at a biological level. Patients with more severe psoriasis consistently show higher rates of depression.

The psychological burden extends to suicidal ideation, with prevalence reported as high as 21% in some psoriasis cohorts.^[14] Routine mental health screening using a validated tool (PHQ-2 or PHQ-9) belongs in psoriasis management, and referral to behavioral health should be offered without stigma when indicated. There is also evidence that effective psoriasis treatment — particularly achieving skin clearance — reduces depression and anxiety scores, closing the loop between inflammatory burden and psychological wellbeing.

Telehealth in Psoriasis: Monitoring, Refills, and What Works Remotely

Psoriasis is one of the conditions most amenable to telehealth management, and the evidence supports this. A patient-centered online care trial published in the Journal of the American Academy of Dermatology found that psoriasis patients managed via online follow-up achieved equivalent reductions in PASI scores compared to in-person care — with no significant difference in quality-of-life outcomes.^[15] More recent remote monitoring studies through 2025 confirm this pattern in specialist-led care settings.^[16]

What telehealth handles well in psoriasis:

• Treatment response monitoring — photo-based assessment of plaque clearance, BSA estimation, and quality-of-life scoring can be performed reliably via secure video or asynchronous photo submission.
• Medication refill management — patients on stable topical regimens, phototherapy maintenance, or established biologics benefit from telehealth refills that avoid unnecessary in-office visits.
• Lab review — for patients on methotrexate, cyclosporine, or apremilast, laboratory results can be reviewed and dose adjustments communicated remotely.
• Comorbidity check-ins — brief PEST screening, depression screening, and cardiovascular risk discussion can all be conducted via video visit.
• Flare triage — patients who know their disease well can often describe flare patterns accurately enough for remote clinical decision-making, reserving in-person visits for new or diagnostically uncertain presentations.

What requires in-person evaluation: suspected new diagnosis or diagnostic uncertainty, skin biopsy, joint examination for PsA assessment, initiation of biologic therapy (which typically requires in-person work-up and education), and any clinical picture suggesting erythrodermic or pustular psoriasis.

From an access standpoint, telehealth is particularly valuable in psoriasis because dermatology wait times in many regions exceed 4–6 weeks. For established patients, remote management maintains continuity without gaps that allow psoriasis to rebound. Patients on biologics who receive regular telehealth follow-up demonstrate higher medication adherence — a clinically meaningful outcome given that adherence gaps are one of the most common reasons for treatment failure.

Frequently Asked Questions